MLT-748
Based on 5 publication(s) in Google Scholar
MLT-748 is a potent, selective and allosteric inhibitor of MALT1, binds MALT1 in the allosteric Trp580 pocket, with an IC50 of 5 nM.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 1832578-30-9
- Formula: C19H19Cl2N9O3
- Molecular Weight:492.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) MLT-748
More
Biological Activity
IC50: 5 nM (MALT1)[1]
Kd: 13 nM (MALT1(329-728)-W580S), 42 nM (MALT1(329-728))[1]
MLT-748 reversibly binds to human mutant MALT1(329-728)-W580S (Kd, 13 nM) with affinity similar to that of the wild type MALT1(329-728) (Kd, 42 nM)[1].
MLT-748 (0-2 μM) stabilizes cellular MALT1-W580S, with an EC50 of 69 nM[1].
MLT-748 (2 μM, 24 hours) increases the phosphorylation of p65 and IκBα in MALT1mut/mut patient immortalized B cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MALT1mut/mut patient immortalized B cells
-
Concentration:2 µM
-
Incubation Time:24 hours
-
Result:Increased NF-κB signaling phosphorylation of both p65 and IκBα as early as 5 min after stimulation with PMA and ionomycin.
Chemical Information
-
CAS No. 1832578-30-9
-
Appearance Solid
-
Molecular Weight 492.32
-
Formula C19H19Cl2N9O3
-
Color White to off-white
-
SMILES
O=C(NC1=CC(Cl)=C(N2N=CC=N2)N=C1)NC3=C([C@@H](OC)[C@H](OC)C)N4C(N=C3)=CC(Cl)=N4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
J Exp Med
2021 Oct 4;218(10):e20202280. PMID: 34406363 -
Cell Signal
The paracaspase MALT1 is a downstream target of Smad3 and potentiates the crosstalk between TGF-β and NF-kB signaling pathways in cancer cells. [Abstract]2023 May:105:110611. PMID: 36708753 -
Int J Biochem Cell Biol
MIEN1 on the 17q12 amplicon facilitates the malignant behaviors of gastric cancer via activating IL-6/JAK2/STAT3 pathway. [Abstract]2024 Nov:176:106666. PMID: 39343060 -
bioRxiv
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression. [Abstract]2024 Sep 27:2024.09.26.614808. PMID: 39386586
Solvent & Solubility
DMSO : 200 mg/mL (406.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0312 mL | 10.1560 mL | 20.3120 mL | 50.7800 mL |
| 5 mM | 0.4062 mL | 2.0312 mL | 4.0624 mL | 10.1560 mL | |
| 10 mM | 0.2031 mL | 1.0156 mL | 2.0312 mL | 5.0780 mL | |
| 15 mM | 0.1354 mL | 0.6771 mL | 1.3541 mL | 3.3853 mL | |
| 20 mM | 0.1016 mL | 0.5078 mL | 1.0156 mL | 2.5390 mL | |
| 25 mM | 0.0812 mL | 0.4062 mL | 0.8125 mL | 2.0312 mL | |
| 30 mM | 0.0677 mL | 0.3385 mL | 0.6771 mL | 1.6927 mL | |
| 40 mM | 0.0508 mL | 0.2539 mL | 0.5078 mL | 1.2695 mL | |
| 50 mM | 0.0406 mL | 0.2031 mL | 0.4062 mL | 1.0156 mL | |
| 60 mM | 0.0339 mL | 0.1693 mL | 0.3385 mL | 0.8463 mL | |
| 80 mM | 0.0254 mL | 0.1269 mL | 0.2539 mL | 0.6347 mL | |
| 100 mM | 0.0203 mL | 0.1016 mL | 0.2031 mL | 0.5078 mL |